超越BCMA:多发性骨髓瘤的新型免疫靶点
本文综述了多发性骨髓瘤在BCMA靶向治疗之外的新型免疫靶点,包括GPRC5D、FcRH5和SLAMF7等,汇总了相关临床试验的关键安全性和有效性数据,并讨论了序贯T细胞重定向治疗、联合治疗及无化疗方案的可行性。
要点
- BCMA靶向治疗改善复发/难治性多发性骨髓瘤生存,但多数患者最终复发。
- GPRC5D、FcRH5和SLAMF7是BCMA之外正在开发的新型靶点。
- 序贯T细胞重定向治疗及联合治疗可行,为无化疗方案铺路。
核心结论
- BCMA靶向免疫治疗革新多发性骨髓瘤治疗并改善复发/难治患者生存,但多数患者最终复发,需BCMA之外的新靶点及序贯T细胞重定向治疗和联合治疗以应对复发,尤其抗原阴性复发。
研究设计与样本
- 本文为综述,总结多发性骨髓瘤BCMA之外新型靶点的开发情况,并呈现可获得的临床试验关键安全性和有效性数据。
主要发现
- 抗体药物偶联物、嵌合抗原受体T细胞和T细胞衔接器靶向BCMA已革新多发性骨髓瘤治疗,改善复发/难治患者生存并正向更早治疗线推进。
- 尽管有效,多数患者最终复发,需要额外靶点用于挽救治疗。
- G蛋白偶联受体C类5成员D、Fc受体同源物5和SLAMF7是正在开发的新型靶点示例。
临床怎么用
- 作者认为,序贯T细胞重定向治疗包括靶向不同肿瘤相关抗原的药物和联合治疗似乎可行,为有效的无化疗方案铺路。
- 作者认为,审慎考虑治疗时机、保护T细胞健康、克服抗原丢失和理解复杂肿瘤微环境是最大化治疗获益和最小化不良反应的关键。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The identification and targeting of B-cell maturation antigen (BCMA) through immunotherapeutic strategies such as antibody-drug conjugates, chimeric antigen receptor T cells, and T-cell engagers have revolutionized the care of patients with multiple myeloma (MM). These treatment modalities have improved the survival outcomes of patients with relapsed and/or refractory MM compared with previously established strategies and are moving into earlier lines of therapy. Despite their efficacy, the majority of patients eventually relapse, necessitating additional therapeutic targets for salvage. G-protein-coupled receptor class 5 member D, Fc receptor-homolog 5, and SLAMF7 are some examples of novel targets in development. This expanding armamentarium of immunotherapeutic agents will be crucial to address the unmet need for relapses after BCMA-targeting therapies, particularly antigen-negative relapses. The utilization of sequential T-cell redirective therapies including agents targeting different tumor-associated antigens and combination therapies appears feasible, paving the way for effective chemotherapy-free regimes. Deliberate consideration of treatment timing, preserving T-cell health, overcoming antigenic loss, and comprehension of the complex tumor microenvironment would be key to maximizing therapeutic benefits and minimizing adverse effects. This review summarizes novel targets in development for myeloma beyond BCMA, presenting pivotal safety and efficacy data derived from clinical trials when available and the considerations vital for navigating this expanding landscape of immunotherapeutic options.
引用
- Tan MSY, Chen Y, Smith EL, et al. Beyond BCMA: newer immune targets in myeloma. Blood Adv. 2024. PMID: 38865708. doi:10.1182/bloodadvances.2023010856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。